Korean MSD held an Open Innovation Week from April 27 to May 1 to expand strategic collaboration opportunities with domestic biotech and pharmaceutical companies, the company announced on Wednesday.
This event, Korean MSD’s first official partnering activity of the year, followed the launch of the MSD BD&L office in Seoul’s Jung-gu district in late April. It aimed to deepen and broaden the decade-long partnership between MSD and the Korean biotech ecosystem.
During the week-long event, Korean MSD conducted one-on-one meetings with 13 domestic biotech and pharmaceutical companies. These meetings took place during the Bosanjin-MSD Partnering Day, co-hosted with the Korea Health Industry Development Institute, and an open innovation session linked to Bio Korea 2026.
Jeong Young-hoon, Planning Director of the Korea Health Industry Development Institute, said that collaborating with Korean MSD on various open innovation initiatives, including the Partnering Day, is significant. It hopes this partnership yields concrete results, such as technology exchanges and joint research projects.
Kim Albert, Chief Executive Officer (CEO) of Korean MSD, stated that Korean MSD is steadily expanding its role as a global collaboration hub for K-Bio, moving beyond merely introducing innovative medicines and vaccines to the Korean market. It’s committed to fostering a long-term partnership that grows in tandem with the Korean biotech ecosystem.
As the Korean subsidiary of global pharmaceutical giant MSD, Korean MSD is ramping up its research and development collaborations and open innovation activities. The company continues to supply innovative medicines to the domestic market, including anticancer drugs, vaccines, and treatments for infectious diseases.